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 _____________________________________________________________________________________________________ 
The wide availability of tomographic images acquired before, 
during and after radiation treatment had offered the 
possibility to improve diagnosis and treatment evaluation in a 
non-invasive way. Image analysis is widely performed to 
extract parameters in different contexts, as, for example, for 
the identification of tumoral tissues with respect to normal 
tissues, for the correct classification of tumor grade, for the 
evaluation of treatment efficacy or its side-effects on organs 
at risks, or for the prediction of radiation-induced toxicities. 
The classical image analysis methods are based on the 
evaluation of some geometric features (volume, dimension, 
short-axis length, …) or the mean gray-level intensity of the 
organ of interest. Also when functional images are considered 
(e.g. PET, DWI-MRI, DCE-MRI), the quantitative analysis of 
functional information is usually carried out in a ROI-based 
approach, considering only the average value within a region 
of interest. However, since the spatial organization of a 
tissue is an important marker both for the identification of 
abnormal tissues and for the evaluation of radiation-induced 
variations, it is worth considering the structural patterns of 
the image, generally lost in a ROI-based approach. For this 
purpose, texture analysis can be very helpful in extracting 
features able to characterize the structural information hold 
in these images. This is true when anatomical images (CT, 
MRI) are considered, because textural features can directly 
reflect the structural properties of the region, but also when 
functional images are analyzed, since the functional behavior 
of a tissue cannot be properly captured by a simple average 
value. Texture analysis can be faced in many different ways; 
the most used in literature are the First-Order statistical 
method, based on the histogram, the second-order statistical 
method, based on co-occurrence matrices, the steerable 
Gabor filter, the fractal-based features, the run length 
matrices and the Fourier transform. These methods, in 
general, extract a large number of features, which can be 
used for classification or prediction models. For this purpose, 
a selection method able to identify the most significant 
parameters is required, followed by an automatic 
classification method (e.g. support vector machine, neural 
networks, random forests, linear discriminant analysis, 
Bayesian methods, fuzzy-logic analysis). In this lesson, some 
of these approaches will be presented, focusing, in 
particular, on statistical and fractal-based methods and their 
biological meaning. Moreover, an overview of the different 
applications of texture analysis in radiotherapic context is 
presented, considering different image modalities (CT, 
anatomical MRI, DWI-MRI, DCE-MRI, PET). In fact, many works 
have applied texture analysis for the characterization of 
tumoral tissue for an automatic identification of radiation 
targets and for the discrimination between abnormal/normal 
tissues. In some cases, it is the power of textural features in 
capturing information about the spatial organization of the 
tissue to be fundamental for a correct discrimination 
between tumoral and normal tissue, rather than the simple 
mean intensity. Another application of texture analysis was in 
the evaluation and prediction of radiation-induced effects on 
tumor and organs at risk. Recently, textural features were 
also proposed as a modulation index in VMAT. 
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The rapid introduction of low LET particle therapy worldwide 
- in particular proton therapy - but also high LET particle 
therapy contrasts with the scarcity of radiobiologic evidence 
to support the expansion of new clinical indications. For 
many years, particle radiobiology research has focused on the 
determination of generic values for the relative biological 
effectiveness (RBE) for both proton and heavy ions, to be 
applied in the clinics and relevant for both tumor control and 
radiation effects in the normal tissue. Nevertheless, recent 
mechanistic-oriented research on the cellular and tissue level 
reveal differential response patterns on the gene expression, 
intracellular signaling, tumor and normal tissue level to low 
and high LET particle therapy and to photon therapy. For 
example, our own studies at the center for proton therapy at 
the Paul Scherrer Institute, but also at other proton therapy 
institutes, reveal a differential requirement of the two major 
double strand break repair pathways in response to proton- 
versus photon-irradiation and indicate individual 
susceptibilities to photon and low LET proton but also high 
LET particle therapy. This has been demonstrated in 
accepted models of genetically-defined normal tissue cells 
and human tumor cells with a defined lack in specific DNA 
repair capacities. Likewise combined treatment modalities 
with pharmacologic inhibitors of specific DNA repair 
machineries sensitize tumor cells for the respective type of 
ionizing radiation. These results might become relevant for 
clinical stratification of patients e.g. carrying mutations in 
specific DNA damage response pathways; ask for the 
identification of relevant functional biomarkers; and the 
critical evaluation of generic RBEs to be applied for the 
different particle-based radiotherapy modalities. Thus, we 
nowadays realize that the RBE can vary significantly 
depending on the tissue, cell line or physiological end point 
investigated and that differential biological processes are 
induced by photon and particle therapy. Here we will discuss 
recent radiobiological findings on the subcellular, cellular 
and tumor microenvironment level in the framework of 
proton and other particle therapies. 
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The strong expression of SSTR2 by neuroendocrine tumors 
(NETs) enables peptide receptor radionuclide therapy (PRRT), 
the molecular internal radiation therapy of NETs. In our 
hospital (certified as ENETS Center of Excellence), a 
dedicated multidisciplinary team of experienced NET 
specialists is responsible for the management of NET patients 
(over 1,200 patient visits per year). Patient selection for 
PRRT is based on the Bad Berka Score (BBS) which takes into 
account clinical aspects and molecular features. Frequent 
therapy cycles (4-6 and up to 10), applying low or 
